Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults

Randomized, double-blind, parallel 16-week study (first 8 weeks double-blind PSIL428 vs placebo; weeks 9–16 open-label PSIL428) evaluating micro-dosed psilocybin (PSIL428, 1 mg) for adults with anxiety and/or depression symptoms.

Primary outcome is change in anxiety and/or depression from baseline to week 16 measured by Beck Anxiety Inventory and Beck Depression Inventory (bi-weekly); safety assessed via labs and adverse events.